Studi clinici su Obesità nello stato di Nevada
29 studi su Obesità cercano partecipanti presso sedi nello stato di Nevada.
Città nello stato di Nevada
Testo ufficiale dello studio (inglese)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Vector Clinical Trials /ID# 282265, Las Vegas
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07752979A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Excel Clinical Research, LLC, Las Vegas
- Palm Research Center Tenaya, Las Vegas
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07783802AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Palm Research Center Inc., Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07720271A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07776509A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Excel Clinical Research, Las Vegas
- Vector Clinical Trials, Las Vegas
In reclutamentoFase 3
Età da 45 a 99 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Palm Research Center Tenaya, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07369011A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743450A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Las Vegas
In reclutamentoFase 3Volontari sani benvenuti
Età da 18 a 79 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Jubilee Clinical Research, Inc., Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07770841A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Vector Clinical Trials, Las Vegas
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT07215559A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Skin Cancer and Dermatology Institute - Reno, Reno
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06857942Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Palm Research Center Inc, Las Vegas
- Vector Clinical Trials, Las Vegas
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Palm Research Center Inc, Las Vegas
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07284901Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Excel Clinical Research, Las Vegas
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07575399Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.
- University of Nevada, Las Vegas, Las Vegas
In reclutamentoVolontari sani benvenuti
Età da 21 a 74 · Tutti i sessi · Aggiornato il 27 ago 2026 · NCT07566325A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- UMC of Southern Nevada, Las Vegas
- Palm Research Center Inc-Vegas, Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Las Vegas
In reclutamentoFase 3
Età da 18 a 79 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT07654361A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Palm Research Center, Mountainview Medical Center, Las Vegas
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT07477704A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Jubilee Clinical Research, Inc., Las Vegas
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 lug 2026 · NCT07481630A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
- Corxel Investigational site, Las Vegas
In reclutamentoFase 1
Età da 18 a 55 · Donne · Aggiornato il 17 giu 2026 · NCT07652047Randomized Trial of Healthy Family Foundations
- Nellis Airforce Base, Nellis Air Force Base
In reclutamentoVolontari sani benvenuti
Età da 18 a 60 · Tutti i sessi · Aggiornato il 14 apr 2026 · NCT05630482Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.